The phase 3 SACHI trial showed that savolitinib + osimertinib significantly improved PFS in MET amp, EGFR -mutated NSCLC after first-line EGFR TKI failure, with a median PFS of 9.8 months vs. 5.4 months for chemotherapy (HR=0.34; p<0.0001). This combination offers a promising chemotherapy-free treatment option for these patients.

In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.

Alterations in the epidermal growth factor receptor (EGFR) gene occur in up to 40% of non-small cell lung cancers (NSCLCs), among which exon 20 insertions are the third most common type of mutation and account for up to 12% of EGFR-mutated (EGFRm) cases.1,2 Exon 20 insertions alter the conformation

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide.1-3 Surgical removal and liver transplantation are preferred, however, only 30% of patients are eligible for curative treatment at presentation.1 Stereotactic body radiotherapy (SBRT) is a promising local

With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab + ipilimumab as a first-line therapy for untreated aRCC.

The ADAURA trial was a randomized, double-blind, placebo-controlled, phase 3 study that evaluated the survival benefits of adjuvant osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), in the treatment of patients with completely resected EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).¹ A total of 682 adult patients with completely resected stage IB, II, IIIA NSCLC were recruited and randomized 1:1 to receive either osimertinib 80mg daily or placebo for 3 years until disease recurrence or treatment completion.¹ The primary endpoint of the ADAURA trial was disease-free survival (DFS) in stage II-IIIA patients.¹ Overall survival (OS) is one of the key secondary endpoints of the ADAURA trial.¹

The CodeBreaK 200 trial was the first randomized, phase 3 trial that compared the efficacy between sotorasib and docetaxel in patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated advanced non-small cell lung cancer (NSCLC).1 A cohort of 345 adults with locally a

Non-small cell lung cancer (NSCLC) accounts for 85%of all types of lung cancer and is the most common cancer in Hong Kong with a total of 5,575 cases in 2019.^1,2 Approximately 30% of NSCLC patients are diagnosed as early stage, and surgical resection is the preferred treatment option for possibly co

The study conducted by a group of researchers from the University of Hong Kong (HKU) has provided insight into the mechanism behind hepatocellular carcinoma (HCC) patient’s resistance to the programmed death 1 (PD-1) immune checkpoint blockade (ICB), contributing to the understanding of HCC therapy